Pharmacological data on combination of astragaloside A with tanshinone IIA inhibits the angiotensin II-stimulated proliferation and migration of vascular smooth muscle cells via the STIM1, TRPC1/6, and NFATc3 signaling pathway

Astragaloside A combined with tanshinone IIA could significantly inhibit angiotensin II-induced VSMC proliferation, migration and [Ca2+]i increases, and this combination was superior to either drug alone and was not significantly different from the TRPC blocker SKF96365. Western blotting revealed that Ang II induced obvious increases in VSMC STIM1, TRPC1, TRPC6, CaN and NFATc3 protein expression and that astragaloside A combined with tanshinone IIA and SKF96365 significantly inhibited the STIM1, TRPC1, TRPC6, CaN and NFATc3 protein expression induced by angiotensin II, indicating that astragaloside A combined with tanshinone IIA has the same blocking effect on TRPC-NFATc calcium signaling as SKF96365 and is better than the application of a single drug alone.